(Reuters Health)—Drug companies generally don’t disclose all the reasons new medicines fail to win U.S. marketing approval, even though regulators often reject treatments over concerns about safety or effectiveness, a study finds. Researchers compared the details companies made public in press releases with confidential documents from the U.S. Food and Drug Administration known as complete…
Biosimilar for Infliximab Launched in Europe
Plus, updates on arhalofenate, ALO-02, and other rheumatology drug news, safety information
The ACR Recommends Cautious Approach as Biosimilars Enter U.S. Market
With the U.S. FDA’s first approval of a biosimilar drug earlier this month, rheumatologists stress the need to ensure safety, efficacy of such drugs in treating rheumatic diseases
Certolizumab Pegol Drug Studies Find No New Safety Issues
Plus, updates on clazakizumab, hydrocodone bitartrate extended-release capsules and other rheumatology drug news, safety information
Drug Interactions for Trimethoprim/ Sulfamethoxazole Come to Light
Plus, updates on buprenorphine, diclofenac sodium, secukinumab and other rheumatology drug news, safety information
2014 ACR/ARHP Annual Meeting: Rheumatology Drug Updates, Safety News
Plus, hydrocodone combination products and brodalumab
Hepatitis Reaction with Rituximab Sparks Drug Safety Alert
The FDA modifies rituximab prescribing information to stress risk of hepatitis B virus reactivation
Hydrocodone Bitartrate, Secukinumab, Varenicline Updates, Trials, Approvals
Plus, rheumatology drug news, safety updates
Decernotinib, Subcutaneous Methotrexate Drug Updates, Trials, Approvals
Plus, rheumatology drug news, safety updates
Rheumatology Drug Updates
Information on new approvals and medication safety that rheumatologists need to know
- « Previous Page
- 1
- …
- 22
- 23
- 24
- 25
- 26
- …
- 28
- Next Page »